A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Corticosteroid-induced osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 06 Jul 2018 Planned primary completion date changed from 3 May 2023 to 2 May 2023.
    • 30 May 2018 Planned End Date changed from 14 Apr 2028 to 26 Apr 2026.
    • 30 May 2018 Planned primary completion date changed from 21 Apr 2025 to 2 May 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top